KPVDosage, Side Effects & Legal Status
KPV is marketed for gut, skin, and inflammation claims, but the evidence base is overwhelmingly preclinical. The commonly repeated dosage charts skip the central fact: there is no established human clinical dose for KPV.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Tripeptide (lysine-proline-valine), the C-terminal sequence of alpha-melanocyte-stimulating hormone · also sold as Lys-Pro-Val, alpha-MSH C-terminal tripeptide
Photo: Eduardo Cano Photo Co. / UnsplashThe studies behind the headline.
Results are reported as published. A result in one population does not establish a benefit in another.
| Study | Population | Observed result | Limit |
|---|---|---|---|
| Dalmasso et al., Gastroenterology | Human intestinal cell lines and mouse colitis models | In DSS mouse colitis, KPV reduced colon myeloperoxidase activity by about 50%; the experiment used five mice per group. | A five-mouse experiment is not human efficacy or human safety evidence. |
| Dalmasso et al., cell experiments | Inflammation-stimulated intestinal epithelial cell lines | At 10 nM, KPV reduced IL-1beta-induced IL-8 mRNA by about 35% in the reported cell experiment. | A molecular result in cultured cells cannot determine a clinical dose or predict benefit in people. |
KPV evidence is weaker than marketing suggests
KPV's key findings come from cell systems and mouse colitis models. That is a materially different evidence standard from a completed human trial, regardless of how confidently a product page describes it.
See how PepGuard separates evidence levels for BPC-157What the literature and self-reports actually say.
| What's cited | Range |
|---|---|
| Established human clinical dose | None |
| Cell experiment | 10 nM KPV in stimulated intestinal epithelial cells |
| Mouse colitis model | 100 micromolar KPV in drinking water |
No human dosing regimen is established by a clinical trial. Preclinical concentrations and animal exposures are listed only to show what was studied in the source literature; they cannot be converted into a human injection, capsule, or 'units' protocol.
Signal strength, not just a list.
How often each effect shows up in the available sources, and how solid that evidence actually is.
| Signal | Frequency | Context |
|---|---|---|
| Human adverse-event profile | unknown / not studied | The core cited study used cell lines and mouse models, not a human safety trial. |
| Product identity and contamination risk | unknown / not studied | Preclinical findings do not verify the purity, concentration, sterility, or contents of a commercial KPV product. |
No FDA-approved KPV medicine or approved indication in the US.
The cited KPV evidence includes cell experiments and mouse colitis models. Those experiments can generate a mechanism hypothesis, but they do not establish clinical efficacy, safety, oral absorption in people, or a dose for a supplement or injection.
Every claim above, traced back.
Primary studies, reviews, regulatory pages, and trial registries. Click through and check them yourself.
KPV questions, answered.
No human clinical dose has been established. Online charts are not a substitute for a dose-ranging human study and should not be presented as a validated protocol.
A key 2008 paper found anti-inflammatory signals in cell systems and mouse colitis models. It did not test KPV as a treatment in people.
No FDA-approved KPV medicine or indication is listed in this report. A compound appearing in supplements or peptide-vendor catalogs is not evidence of approval.
Keep researching.
This is a preview of the KPV report.
Create your account to check any peptide against the full research base.